Featured Research

from universities, journals, and other organizations

Hormone mimic reduces liver damage caused by common genetic kidney disease

Date:
May 4, 2010
Source:
American Society of Nephrology
Summary:
A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to new research. The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

A hormone mimic called Octreotide may be effective for treating polycystic liver disease (PLD) caused by ADPKD, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The study is the first clinical trial performed in the United States to test the effects of this agent in PLD.

Related Articles


In addition to causing kidney failure, ADPKD also often leads to PLD, a condition characterized by multiple variably-sized cysts in the liver. Octreotide mimics the somatostatin hormone that regulates the secretion of several other hormones in the body. Somatostatin exerts its effects by blocking both the formation of the chemical cyclic AMP and the secretion of fluids by cells, two factors thought to play a role in the development of kidney and liver cystic diseases.

Marie Hogan, MD, PhD (Mayo Clinic College of Medicine) and her colleagues designed a clinical trial to examine whether Octreotide could shrink the cyst-filled livers of patients with PLD. The randomized, double blind, placebo-controlled trial enrolled 42 patients with severe PLD caused by ADPKD (34 patients) or autosomal dominant PLD (8 patients). (Autosomal dominant PLD is a genetic form of PLD not caused by ADPKD.)

Patients received Octreotide or placebo, and treatments were administered as monthly injections.

After one year, liver volume decreased by an average of approximately 5% in patients taking Octreotide but slightly increased (by approximately 1%) in patients taking placebo. Octreotide also had an effect on the diseased kidneys of patients with ADPKD.

Among these patients, total kidney volume remained practically unchanged in the Octreotide group but increased by more than 8% on average in the placebo group.

Kidney function was similar in both groups of patients. Octreotide was well tolerated, and treated individuals reported an improved perception of bodily pain and physical activity.

"In summary, Octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile," said Dr. Hogan.

Study co-authors include Tetyana Masyuk, PhD, Linda Page, Vickie Kubly, Eric Bergstralh, Xujian Li, Bohyun Kim, MD, Bernard King, MD, James Glockner, MD, PhD, David Holmes III, PhD, Sandro Rossetti, MD, PhD, Peter Harris, PhD, Nicholas LaRusso, MD, and Vicente Torres, MD, PhD (Mayo Clinic College of Medicine).

In reviewing the results of Dr. Hogan's study in an accompanying editorial, Robert Schrier, MD (University of Colorado Denver) noted that they support the findings of earlier animal and human studies and give hope that increases in polycystic liver and kidney volume can be attenuated in patients with ADPKD. He added that additional, larger studies are needed to verify the results and to demonstrate whether Octreotide can provide meaningful health benefits to patients.

Disclosures: Funding support for the study was provided by Mayo Foundation for Medical Education and Research and Novartis USA. Dr. Hogan received partial funding support for this study from Novartis USA. Dr. LaRusso and Dr, Masyuk are named inventors on pending patent applications filed by Mayo Clinic claiming methods for using somatostatin analogs to treat polycystic liver disease. Dr. Schrier, the author of the editorial, is a consultant for Otsuka Pharmaceuticals.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal References:

  1. Marie C. Hogan, Tetyana V. Masyuk, Linda J. Page, Vickie J. Kubly, Eric J. Bergstralh, Xujian Li, Bohyun Kim, Bernard F. King, James Glockner, David R. Holmes III, Sandro Rossetti, Peter C. Harris, Nicholas F. LaRusso, and Vicente E. Torres. Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society Nephrology, 2010; DOI: 10.1681/ASN.2009121291
  2. Robert W. Schrier. Randomized Intervention Studies in Human Polycystic Kidney and Liver Disease. Journal of the American Society Nephrology, 2010 DOI: 10.1681/ASN.2010030262

Cite This Page:

American Society of Nephrology. "Hormone mimic reduces liver damage caused by common genetic kidney disease." ScienceDaily. ScienceDaily, 4 May 2010. <www.sciencedaily.com/releases/2010/04/100429172958.htm>.
American Society of Nephrology. (2010, May 4). Hormone mimic reduces liver damage caused by common genetic kidney disease. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2010/04/100429172958.htm
American Society of Nephrology. "Hormone mimic reduces liver damage caused by common genetic kidney disease." ScienceDaily. www.sciencedaily.com/releases/2010/04/100429172958.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins